| MODEL | NOV 2017 / NOV 2016 | NOVEMBER 2017 | NOVEMBER 2016 | YTD 2017 / YTD 2016 | YTD 2017 | YTD 2016 |
|---|---|---|---|---|---|---|
| MUSTANG | +8.46% | 6,720 | 6,196 | -25.00% | 74,152 | 98,868 |
The Mustang’s November sales performance enabled it to remain the best-selling vehicle in its segment. By comparison, Chevy Camaro sales decreased 3 percent to 4,737 units while Dodge Challenger sales decreased 1 percent to 3,860 units. As such, not only did the Mustang remain the segment best-seller, but it also was the only car in its segment to post a sales uptick.
| MODEL | NOV 17 / NOV 16 | NOVEMBER 17 | NOVEMBER 16 | YTD 17 / YTD 16 | YTD 17 | YTD 16 |
|---|---|---|---|---|---|---|
| MUSTANG | +8.46% | 6,720 | 6,196 | -25.00% | 74,152 | 98,868 |
| CAMARO | -3.19% | 4,737 | 4,893 | -2.38% | 64,138 | 65,705 |
| CHALLENGER | -1.23% | 3,860 | 3,908 | +1.44% | 60,029 | 59,176 |
| MX-5 MIATA | +25.84% | 487 | 387 | +23.69% | 10,801 | 8,732 |
| 86 | -11.11% | 456 | 513 | -6.94% | 6,421 | 6,900 |
| 370Z | -5.88% | 320 | 340 | -22.27% | 4,310 | 5,545 |
| 124 SPIDER | -23.43% | 268 | 350 | +88.36% | 4,191 | 2,225 |
| BRZ | +8.94% | 256 | 235 | -2.37% | 3,834 | 3,927 |
| TC | * | 0 | * | * | 197 | * |
| TOTAL | +1.68% | 17,104 | 16,822 | -9.16% | 228,073 | 251,078 |
November sales of the mainstream two-door sports car segment consisting of the Ford Mustang, Chevy Camaro, Dodge Challenger, Mazda MX-5 Miata, Toyota 86 (née Scion FR-S), Nissan 370Z, Subaru BRZ, Fiat 124 Spider and Scion tC increased 1.68 percent to 17,104 units. In the first 11 months of the year, segment sales decreased are down 9 percent to 228,073 units with the Mustang leading in overall sales volume, the Camaro in second place and the Challenger in third.
Low-interest financing offered on heavy-duty pickup truck.
It just published another patent for that kind of feature.
Based on requests from domestic automakers and trade groups.
It isn't real, but maybe some folks wish it was.
A list it's been on for years now.
A recent study found three areas of concern.